



**Press Release**

**Source: CLX Investment Company**

## **CLX Investment Company Announces Appointment of Vera Leonard as CEO**

Issued Thursday November 1, 9:26 am ET

MURRIETA, CA--(MARKET WIRE)--Nov. 1, 2007--CLX Investment Company, Inc. (OTC BB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today announced that at a recent meeting of the Board of Directors, Vera Leonard was appointed to the position of president and chief executive officer to fill the vacancy created by the recent resignations of Steven R. Peacock as consultant chief executive officer and Robert McCoy as president. Mr. McCoy will remain in his position as chairman of the Board of Directors.

A Current Report on Form 8-K with the details of this appointment will be filed with the Securities and Exchange Commission.

Ms. Leonard, who has served as CEO of Zonda since August of 2007 and will retain that title, brings to CLX considerable successful experience in leadership positions with major medical manufacturing and distribution companies.

As vice president of U.S. sales for a Nasdaq listed company that specializes in rapid, point of care diagnostic tests, Ms. Leonard led negotiations on agreements that added approximately \$8 million in annual revenue and helped to grow revenues from \$32 million to \$51 million in 3 years. She delivered an unprecedented 6 consecutive quarters of financial performance that met or exceeded expectations and saved more than \$1,500,000 annually for the company from renegotiations of growth incentive plan, implementation of net pricing strategy and elimination of GPO administration fees.

Ms. Leonard received awards for outstanding sales performance and distribution partnering from industry-leading distributors 3 years in a row and 4 years total. She restructured the sales and support organization to establish standards of performance, goal-driven compensation plan, territory-level budget and forecast management while developing individuals for promotion to levels of greater responsibility and leadership.

Ms. Leonard also served as director of vendor relations for a Fortune 500 distributor of medical and dental supplies to office-based practices worldwide. In this position, she

launched 6 new products; negotiated semi-exclusive distribution rights on three innovative new products; designed a product launch template that was adopted for standard use by the entire medical marketing team; negotiated an exclusive special pricing agreement on market-leading product to maximize competitive conversions; and completed an in-depth pricing analysis by vendor, sales division and SKU to assess pricing strategies and assure competitive positioning while maximizing profitability.

Previous to these positions, Ms. Leonard served as sales representative, sales manager, regional sales manager, and national sales manager for medical manufacturing and distribution companies where she developed an extensive firsthand knowledge of the medical supply field. These companies ranged from start-ups to major U.S. and international firms.

“Ms. Leonard has already made tremendous strides within Zonda, and we believe that she is the right person to lead CLX as it seeks to deliver long term value to the company’s shareholders,” stated Robert McCoy, chairman of CLX Investment Company. “Ms. Leonard’s significant experience in the medical diagnostic testing industry provides the opportunity for CLX to not only maximize the potential value of Zonda, but to also explore opportunities to target additional medical testing technologies that can be developed as assets for the public company.”

Ms. Leonard commented, “I am pleased to accept the appointment to the position of president/CEO of CLX Investment Company and look forward to working with the Board to execute the company’s business strategy. I intend to address CLX shareholders in the very near future on specific issues related to Zonda and how we expect to grow this subsidiary in the medical diagnostic testing market.”

Zonda’s tests utilize proprietary technology that detects enzymes that are specific to the target microorganisms. The Zonda medical diagnostic tests are ideal for the clinical laboratory, point of care, and the over-the-counter (OTC) markets.

Zonda’s intellectual property position in enzymatic detection technology will give the company a unique position in the clinical diagnostic market where there is increasing need for simple, reliable, and cost-effective rapid point of care diagnostic tests. The company’s first medical test for *Chlamydia* is currently sold throughout Europe under the HandiLab brand, and a U.S. launch is being planned. Zonda believes it will compete successfully with all current technologies, including the “gold standard” nucleic acid amplification testing (NAAT) technology, while offering several enhanced features.

More information regarding Zonda can be found on its official website, [www.zondaincusa.com](http://www.zondaincusa.com).

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit <http://www.clxinvestments.com/email.php>.

#### About CLX Investment Company

CLX Investment Company ([www.clxinvestments.com](http://www.clxinvestments.com)) holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. ([www.actionviewinternational.com](http://www.actionviewinternational.com)), a publicly traded global manufacturer and marketer of “smart” scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments’ control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

#### Contact:

Gemini Financial Communications

A. Beyer

951-677-8073

[investors@clxinvestments.com](mailto:investors@clxinvestments.com)